anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
1399632 Diuretic &amp;c medicines LEO PHARMACEUTICAL PRODUCTS Ltd AS (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) 6 July 1973 [13 July 1972 7 Nov 1972 24 Jan 1973] 32909/72 51384/ 72 and 3658/73 Heading A5B [Also in Division C2] Pharmaceutical compositions having diuretic and saluretic actions contain (I) as active ingredient in which R 1 is a substituted or unsubstituted C 1 -C 6 alkyl, alkenyl or alkynyl radical, or a C 1 -C 3 alkyl radical substituted with a phenyl, substituted phenyl or an unsubstituted or substituted 5- or 6-membered heterocyclic radical containing not more than two hetero atoms selected from oxygen, sulphur and nitrogen atoms; R 2 is a substituted or unsubstituted phenyl radical; X and Y are each an oxygen or sulphur atom; and pharmaceutically acceptable, non-toxic salts of the carboxylic acid of formula I; and esters thereof with cyanomethanol, benzyl alcohol, and C 1 -C 6 alkanols. The compositions may further contain other therapeutic compounds applied in the treatment of, for example oedemas and hypertension, besides the well-known auxiliary agents. Such other compounds may be, for instance, Veratrum- or Rauwolfia alkaloids, e.g. reserpine, rescinnamine or protoveratrine or synthetic hypotensive compounds, e.g. hydralazine, or other diuretics and saluretics, such as the wellknown benzothiadiazines, e.g. hydroflumethiazide, bendroflumethiazide. Potassium-sparing diuretics, e.g. triamterene, may also be used in the preparation of the compositions. For some purposes it may be desirable to add small amounts of aldosterone antagonists, e.g. spironolactone. Administration is orally, parenterally or enterally.
[GB1399632A]
The invention concerns a novel method for preparing substituted anthraquinone represented by the general formula (I) in which R represents a hydrogen atom or a linear or branched alkyl group of 1 to 5 carbon atoms, a chloromethyl group, a -COCl group, a COOR&#39; group or a -CH¿2?OR&#39; group in which R&#39; is a hydrogen atom or a linear or branched alkyl group of 1 to 5 carbon atoms, R¿1? represents a hydrogen atom, a hydroxyl group, a linear or branched alkyl group of 1 to 5 carbon atoms, or an acyloxy group of 1 to 5 carbon atoms, and R¿2? represents a hydrogen atom, by Diels-Alder reaction between a 1,4-naphthoquinone of general formula (II): in which R¿2? is as defined above, and X represents a hydrogen or halogen atom and an acyclic diene of formula (III): CH¿2? = CR - CH -OR¿2? in which R is as defined above, and R¿3? represents a silyl group of formula -Si(R¿4?)¿3? in which R¿4? is a linear or branched alkyl group of 1 to 5 carbon atoms, followed by an oxidising deprotecting reaction using Jones reagent for obtaining substituted anthraquinone of general formula (I). The invention is for preparing rheins useful in pharmaceutics.
The present invention relates to a preparation method for mesenchymal stem cell preparation, the best external neural induction time, the best mixing ratio of the external neural induction time and controlled and released neurotrophic factors, and a new technique used for treating central nervous systems of brain and spinal cord and other diseases. The preparation method of mesenchymal stem cells comprises the steps of cultivating a mesenchymal stem cell, inducing the mesenchymal stem cell outside a human body; together applying the induced mesenchymal stem cell and the controlled and released glial cell-derived neurotrophic factors. The present invention also comprises the application of the mesenchymal stem cell prepared by the method to the preparation of a drug used for repairing the damage to central nerves. The present invention determines the best neural induction time and the best ratio between the MSC and the controlled and released GDNF. Through a partial transplant combination method, the functions of damaged monkey&#39;s spinal cords are recovered and the structure is repaired. The present invention provides an instruction method for the joint application of cell and biological engineering materials. Therefore, the present invention is an effective strategy for treating spinal cord injury and related diseases, and has a wide clinical and developmental prospect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic method for a malignant tumor in which a cell-specific expression replication vector is constructed in order to treat the malignant tumor by expressing and replicating a gene in a specific cell, for example, that of the malignant tumor while normal cells may not be damaged, wherein the vector is transferred into the specific living cell, e.g. the malignant tumor cell, and expressed for treatment.  &lt;P&gt;SOLUTION: A transcription initiation control region of human calponin gene specifically expressed in a cell is acquired and linked to the upstream portion of a replication-related gene for a virus, e.g. ICP4. A DNA encoding the protein of vascularization inhibitory factor or apoptosis-relating factors is linked through IRES to the replication-related gene for the virus, while a thymidinekinase gene is left intact. The resultant DNA sequence is incorporated into a virus DNA to construct the cell-specific expression replication vector and the constructed vector is infectively transferred into the malignant tumor cell to selectively break the tumor cells.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To orally administer a precursor of adenosine triphosphate as dietary supplements to increase the intracellular ATP concentration or to deal with reduction of energy availability resulting from strenuous physical activity, illness or trauma.  &lt;P&gt;SOLUTION: Pentose sugars are administered individually, or mixed into dry food or solution. Preferred pentose is ribose, used singly or with creatine, pyruvic acid, L-carnitine and/or vasodilating agents. Additionally, magnesium, electrolytes, fatty acids and hexose sugars can be used. The compositions and methods are especially beneficial to mammals having reduced energy availability or high energy demand.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to medicine and pharmaceutical industry. Pharmaceutical composition has as active substance clozapine and auxiliary substances: hydroxypropylmethylcellulose (HPMC), micro crystalline cellulose modified by silicon dioxide (MCC MSD) and magnesium stearate. Pharmaceutical composition is made in from of coated pills. Coating contains &#34;Opadry II&#34; of Colorcon company or composition, which consists of polyvinyl alcohol, titanium dioxide, polyethylene glucole and acceptable dyes. Pharmaceutical composition of prolonged action based on clozapine has 2 year storage term. ^ EFFECT: obtaining pharmaceutical composition based on clozapine, relating to group of atypical neuroleptics for treatment of various forms of schizophrenia. ^ 6 cl, 1 dwg, 4 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To facilitate a nurse taking record during an operation and facilitate a physician making a report after the operation.  &lt;P&gt;SOLUTION: An instrument information input means is comprised of mobile apparatuses such as portable terminals and is equipped with a bar code reader, etc., possible for information inputting directly in an operation room to be able to read the bar code information of labels, etc., pasted on the instruments. The nurse can easily input the instrument information, etc., in real-time during the operation using the instrument information inputting means. The inputted instrument information, etc., are memorized together with the operating time. The physician can make a report using these information after the operation.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. &lt;??&gt;IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. &lt;??&gt;Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.
NEW MATERIAL:The compound of formula I (R&lt;1&gt; and R&lt;2&gt; together form keto group or one of them is H and the other is OH; R&lt;3&gt; is H or acetoxy; n is 0 or 1; when the bond between 8 and 12 positions is double, n is 0; a-e are 1 or 2; the dotted line represents single or double bond). USE:Antiphlogistic agent. PROCESS:Clavularia viridis (a kind of coral) is roughly extracted with ethanol, and the extract is concentrated and further extracted with ethyl acetate in an aqueous system. The obtained extract is fractionated by silica gel chromatography, and the compounds of formula II, III and IV are separated from each fraction. The compounds are subjected to e.g. reduction, oxidation, acetylation, etc. to afford another compound of formula I .
This study is a single-center, prospective observational research . It is divided into two parts: the first part aims to explore and establish a stable and optimal depth of sedation during gastroscopy, while the second part focuses on the same goal during colonoscopy. The purpose of the study is to utilize qCON and qNOX technologies to assess patients\&#39; sedation and analgesia status during painless gastrointestinal endoscopy, combined with visual assessments (cough reflex, respiratory depression, and limb movement) and clinical physiological monitoring (vital signs and pulse oximetry). The goal is to prevent potential adverse events related to sedation and to explore and establish a stable and optimal depth of sedation for anesthesia. Research method: 110 patients undergoing painless gastroscopy and 110 patients undergoing painless colonoscopy were included. During the procedures, qCON and qNOX will be continuously monitored,and anesthesia induction drugs were given: 1.5-2.5mg/kg propofol, 3-5 μ g sufentanil; The injection speed of propofol is between 120s and 180s. During the inspection, pump propofol at 4-12mg/kg · h to achieve MOAA/S ≤ 1, and there is no body movement reaction.The primary endpoint will be the quality of sedation during the passage of the gastroscope through the oropharynx and during the passage of the colonoscope through the anus. Secondary endpoints will include qCON and qNOX measurements at different time points during the gastroscopy and colonoscopy, hemodynamic changes, and the incidence of adverse events.
PURPOSE:To reduce the recording capacity of a recording section, to reduce time required for section converting process and to facilitate picture display by cutting out only the areas of concern from picture data for plural sheets and recording and reproducing them. CONSTITUTION:The area of a concern R is set in a state that the first picture data D1 are displayed in a display unit 6, and the address data and patient information are sent to a CPU 9. The CPU 9 records the picture data D1 together with the patient information in a picture data storing section 11, and at the same time, stores address data in an address data recording section 12. Then, the picture data D1 and address data are read out and sent to a display unit 6A. The second picture data D2 are displayed in a display unit 6 and only the picture data D&#39;2 of a part corresponding to the area of the concern R are recorded in the adjoining part of recording area of picture data D1 in the picture recording section 11. After making the section converting process of the picture image data D&#39;2 by controlling a section converting section 13, the data are sent out to the display unit 6A.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a water-in-oil type cosmetic which has excellent makeup retainability, has good skin compatibility, is freshly, has smooth spreadability, and has excellent temporal stability.  &lt;P&gt;SOLUTION: This water-in-oil type cosmetic is characterized by comprising the following components (A), (B) and (C). The component (A) is one or more compounds selected from the group consisting of an ester compound of erythritol and / an erythritol condensation product with a fatty acid, a polycondensation product of the ester compound, a polybasic carboxylic acid, and erythritol and / an erythritol condensation product, a polycondensation product of a fatty acid with a polycondensation product of erythritol and / an erythritol condensation product with a polybasic carboxylic acid, and a polycondensation product of a fatty acid, a polybasic carboxylic acid and erythritol and / an erythritol condensation product. The component (B) is a surfactant. The component (C) is an aqueous component.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Steroid hormones are solubilized by a pyridine derivative of formula &lt;FORM:0761618/VI/1&gt; where R is an alkoxy, amino or substituted amino radical. Specified derivatives include methyl nicotinate, ethyl nicotinate, methyl isonicotinate, nicotinamide, N, N-diethyl nicotinamide, isonicotnic acid hydrazide and pyrizinamide. Adrenal hormones (cortisone, hydrocortisone, corticosterone, desoxycorticosterone and dehydrocorticosterone), estrogenic hormones (a -estradiol), corpus luteum hormone (progesterone) and androgenic hormones (testosterone), alone or mixed, may be solubilized.  The composition gives a solution on addition of water or a medicinally acceptable oil.  Benzyl alcohol may also be present.  The solutions formed may be used for oral, topical, intramuscular, intravenous, opthalmic, nasal or irrigational administration.  An example describes the preparation of an aqueous solution of hydrocortisone alcohol and nicotinamide.
PCT No. PCT/GB93/02190 Sec. 371 Date Apr. 20, 1995 Sec. 102(e) Date Apr. 20, 1995 PCT Filed Oct. 22, 1993 PCT Pub. No. WO94/10145 PCT Pub. Date May 11, 1994Compounds of formula (I)    &lt;IMAGE&gt;  (I)  wherein one of X and Y represents nitrogen, and the other of X and Y represents oxygen, sulphur or N-R2; Q represents a substituted five- or six- membered monocyclic heteroaliphatic ring which contains one nitrogen atom as the sole heteroatom and is linked to the five-membered heteroatomic ring containing the moieties X and Y via a carbon atom; as well as substituted 1,3-dioxopropane precursors thereto, are ligands for dopamine receptor subtypes within the body and are therefore useful in the treatment of disorders of the dopamine system, in particular schizophrenia.
The present invention provides effective compositions, methods and uses for delivering nucleic acids to cells. The inventive compositions and methods are based upon the surprising discovery that the presence of an endosomal membrane destabiliser in a lipid formulation leads to a dramatic increase in transfection efficiency. The present compositions and methods can be used in vitro or in vivo, and can be used to increase the transfection efficiency of any cell type, including mammalian cells (e.g., humans). In certain embodiments, the conjugated lipid that inhibits aggregation is a &#39;cationic polymer lipid&#39; (CPL). In preferred aspects, the CPL has the formula (I). In formula (I), A is a lipid moiety, W is a hydrophilic polymer, and Y is a polycationic moiety. In certain preferred embodiments, Y is selected from lysine, arginine, asparagine, glutamine, and combinations thereof. In another embodiment, the present invention provides a method for introducing a nucleic acid into a cell, comprising contacting the cell with a nucleic acid-lipid particle composition, wherein the particle comprises a cationic lipid, a conjugated lipid that inhibits aggregation of particles, a nucleic acid; and an endosomal membrane destabilizer. The endosomal membrane destabilizer can be inside the particle, outside the particle, or both inside and outside the particle. In certain embodiments, the endosomal membrane destabilizer contacts the cell before the particle, after the particle, simultaneously or combinations thereof. In still another embodiment, the present invention provides a method for inducing HII phase structure in a lipid bilayer, comprising contacting the lipid bilayer with an endosomal membrane destabilizer, thereby inducing HII phase structure in the lipid bilayer. In certain aspects, the endosomal membrane destabilizer (e.g., Ca++ion) acts synergistically or additively with low levels of the cationic lipid to trigger H¿II? phase formation.
The invention discloses a method for preparing tetanus human immune globulin by double virus inactivation. The method comprises separating and purifying blood plasma from healthy people containing high-potency tetanus antibody by a low-temperature ethanol protein-separating method, and inactivating virus at the pH value of 4.0 after incubation at 23-25 DEG C for 21 days and treating with DV50 nanometer anti-virus membrane for double virus inactivation. The method of the invention has the beneficial effects that the tetanus human immune globulin prepared by double virus inactivation can greatly reduce disease transmitted by blood products, and the quality of products fully complies with the requirement of Pharmacopoeia of People&#39;s Republic of China. Through a test using the pseudorabies virus, Sindbis virus and human immunodeficiency virus (HIV), the virus titer (TCID50) can be decreased by at least 4.00log. The safety and reliability of the products are ensured. The tetanus human immune globulin is particularly suitable for people allergic to tetanus antitoxin (TAT).
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used in lagophthalmos surgery. That is ensured by exposure of the upper conjunctival fornix that is followed with the injection of the preparation &#34;Disport&#34; within the mid-third of the elevating muscle of upper eyelid. The preparation is injected in dosage 20-25 Units at a depth of 0.7-1.0 cm of the eyelid in one or two points spaced 0.5 cm. ^ EFFECT: method is easy to implement and allows providing effective denervation of the related muscle and extending the upper eyelid due to the specified doses and introduction regions. ^ 2 ex
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to field of medicine and veterinary, namely to chemical-pharmaceutical industry, in particular to psychotropic medications. Invention represents pharmaceutical composition, which contains mixture of zolpidem and -cyclodextrin solutions in dimethyl sulfoxide with molar ratio of components from 1:1 to 10:1 with the following final concentration of components in composition based on 0.9% sodium chloride solution: zolpidem 1ù10-4 M, -cyclodextin - from 1ù10-5 to 1ù10-4 M, dimethyl sulfoxide - 10%. Invention can be used for optimisation of adaptive capacities in extreme situations; for treatment of insomnia; correction of anxiety disorders, neuroses, increased nervous excitability or depression; treatment of somatic diseases, accompanied by sleep disorders (syndrome of obstructive sleep apnea-hypopnea, cardio-vascular and nervous system diseases); optimisation of &#34;sleep-wake&#34; cycle in stress situations. ^ EFFECT: invention possesses sedative, nootropic and anxiolytic action, without causing side effects in form of myorelaxation and inhibition of actibating systems of brain stem, characteristic of sedative medications with anxiolytic activity. ^ 3 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antiallergic composition, based on consideration of pharmacological action of Xiangru (an extract of whole grass of Mosla chinensis Maxim. ) which is a crude medicine, particularly Mosla chinensis Maxim. or Elsholtzia ciliata Hylander and having excellent antiallergic action based on chemical mediator isolation-suppressing action which the extract has and degranulation-inhibiting action.  &lt;P&gt;SOLUTION: The antiallergic composition comprises an extract of Xiangru with a solvent as an active ingredient, and the Xiangru to be extracted is Mosla chinensis Maxim. or Elsholtzia ciliata Hylander and the solvent for extraction is water, a lower alcohol or a mixture of the lower alcohol with water, preferably ethanol. The antiallergic composition includes a food, especially a food for specified health use, a medicine, a cosmetic, etc.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a coating apparatus and method which enable the continuous and moreover contactless implementation of a tablet coating treatment.  &lt;P&gt;SOLUTION: The tablet coating apparatus 1 is provided with a belt conveyor 11 for continuously conveying tablets 16 in one direction. A nozzle head 10 with a jet nozzle 41 using a piezoelement is provided nearly at the central part of the belt conveyor 11. The nozzle head 10 has the same structure as that of the printer head of the ink jet printer to make microscopic liquid drops of a coating base material spray through it. The microscopic liquid drops of the coating base material are sprayed onto the tablets on the belt conveyor 11 from the nozzle head 10 to form a skin film of the coating base material on the surface of each tablet 16. The tablets 16 undergo a contactless and continuous coating treatment being conveyed with the belt conveyor 11.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A method in accordance with a particular embodiment of the present invention includes increasing a concentration of a modified or unmodified saccharide within a subject&#39;s skin, applying an applicator to the subject&#39;s skin, and cooling the subject&#39;s skin via a heat-transfer surface of the applicator. The saccharide within the subject&#39;s skin can enhance a resistance of at least some cells within the subject&#39;s skin to damage associated with the cooling. A corresponding system includes the applicator, the saccharide, and an energy-delivery device. The energy-delivery device can be configured to apply ultrasound, optical, thermal, or another type of energy to the subject&#39;s skin to drive the saccharide into the subject&#39;s skin. The system can also include a penetration enhancer configured to enhance penetration of the saccharide into the subject&#39;s skin. The penetration enhancer can be applied with the saccharide or separately.